May is National Cancer Research Month

For an overview of the research done at the James, please read the research section of the 2012 Accomplishments report.

To learn more about the American Association for Cancer Research and National Cancer Research Month, please visit their website.

PTCL: Should Initial Management Include High-Dose Therapy with Autologous Stem Cell Rescue?
Oncology Times
The International Congress on Hematological Malignancies kicked off in New York City with a debate on a challenging malignancy, peripheral T-cell lymphoma (PTCL), and the role of high-dose therapy with autologous stem cell rescue (HDT/ASCR) as initial management. Most PTCL subtypes have a worse prognosis than that for aggressive B-cell non-Hodgkin lymphoma, with a median overall survival time of one to three years, and a five-year overall survival rate of 26 percent. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is an exception, with a five-year survival rate of 65 to 90 percent. Lauren Pinter-Brown, MD, Clinical Professor of Medicine and Director of the Lymphoma Program at David Geffen School of Medicine at UCLA, argued in favor of HDT/ASCR for PTCL, but not for all patients; and Pierluigi Porcu, MD, Associate Professor Internal Medicine at Ohio State University, argued against that treatment, but also with exceptions.
Oncology Times:
On The Move
ThisWeek Community News (Upper Arlington)
The American Association for Cancer Research honored Dr. Carlo Croce, professor and chairman of the department of molecular virology, immunology and medical genetics and director of Human Cancer Genetics at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, with the seventh annual Princess Takamatsu Memorial Lectureship at the recent AACR Annual Meeting 2013 held in Washington, D.C. Croce, an Upper Arlington resident who presented the lecture "Causes and Consequences of microRNA Dysregulation in Cancer," was recognized for his research into the genetic mechanisms of cancer. He discovered numerous oncogenes and established the role of microRNAs in the development and progression of cancer. This coverage resulted from a news release distributed by Ohio State University Wexner Medical Center Public Affairs and Media Relations, available online at
ThisWeek Community News:
Ohio Colorectal Cancer Prevention Initiative (OCCPI)
Through the efforts of the community and funding support from Pelotonia, the OSUCCC – James has formed Ohio Colorectal Cancer Prevention Initiative (OCCPI), a collaboration among many hospitals throughout the state to reduce illness and death due to colorectal cancer in Ohio. Through this initiative, all individuals in Ohio who are newly diagnosed with colorectal cancer will be screened for the most common type of inherited colon cancer (Lynch syndrome). Screening all colorectal cancers for Lynch syndrome, also known as Universal Screening for Lynch syndrome, will help provide correct screening recommendations for high-risk individuals and their families, as well as access to genetic counseling and testing.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: